Immunoliposomes (ILs), obtained with monoclonal antibodies (mAbs) decorating the liposome surface, are used for cancer treatment. These mAbs provide the recognition of molecules upregulated in cancer cells, like Programmed Death-Ligand 1 (PD-L1), an immunecheckpoint involved in tumor resistance, forming a complex that blocks this molecule and thereby, induces antitumor immune response. This mechanism introduces a new concept for ILs. ILs coupled to anti-PD-L1 or its Fab’ fragment have been developed and in vitro/in vivo characterized. Factors such as coupling methods, PEG density and ligand size were optimized. In vitro data showed that Fab’-ILs displayed the highest PD-L1 cell interaction, correlating with a higher in vivo tumor accumulation and an increase of effector cytotoxic CD8+ T cells, providing tumor shrinkage and total regression in 20% of mice. Therefore, a novel immune-nanoplatform able to modulate the immune system has been developed, allowing the encapsulation of several agents for combinatorial therapies.

Additional Metadata
Keywords Liposome, Immunoliposome, PD-L1, PEG, Coupling method, Immunotherapy
Persistent URL,
Journal Nanomedicine-Nanotechnology Biology and Medicine
Merino, M., Contreras, A, Casares, N., Troconiz, I. F., ten Hagen, T.L.M, Berraondo, P., … Garrido, MJ. (2019). A new immune-nanoplatform for promoting adaptive antitumor immune response. Nanomedicine-Nanotechnology Biology and Medicine, 17, 13–25. doi:10.1016/j.nano.2018.12.016